ArticleGland surgery2026
Malignant salivary gland tumors in Brazil: epidemiology, treatment patterns, and survival outcomes in public Brazilian population.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant salivary gland tumors are rare and heterogeneous neoplasms, and population-based data from low- and middle-income countries remain scarce. This study aimed to describe the epidemiology, treatment patterns, overall survival (OS), and prognostic factors of salivary gland cancers in Brazil. Methods: A cross-sectional study using national-level data obtained from the Brazilian Hospital Cancer Registry Integrator describes epidemiological aspects while a retrospective longitudinal study was performed to assess OS using data from the São Paulo State Cancer Registry [Fundação Oncocentro de São Paulo (FOSP)]. Histologies were grouped into five categories: acinic cell carcinoma, adenocarcinoma/ductal carcinomas, biphasic tumors, mucoepidermoid carcinoma, and not otherwise specified (NOS). Results: A total of 4,283 patients were identified in the national cohort and 1,238 in the FOSP cohort between 2005 and 2018. The parotid gland was the most frequent primary site, and surgery with or without radiotherapy was the predominant treatment modality. Median follow-up in the FOSP cohort was 8.4 years. Five-year OS varied across histologies, ranging from 35% in NOS tumors to 88% in acinic cell carcinoma. In multivariable analyses, advanced age, male sex, advanced clinical stage, and histological subtype were independently associated with poorer prognosis. Conclusions: We demonstrated significant variability in survival by histology and identified associations between social and healthcare inequities in univariable analyses, although these were not retained as independent prognostic factors after multivariable adjustment. These findings provide the first large-scale evidence on malignant salivary gland tumors in Brazil, offering critical insights to inform cancer control strategies in similar upper-middle-income country settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.